- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Diversity, Equity, & Inclusion
- Community Advisors
- Contact Us
- Events
- Resource Center
- PKD & Rare Kidney Diseases
- Anemia Associated With CKD
- CKD & Related Comorbid Conditions
- End-Stage Kidney Disease & Renal Replacement Therapies
- Electrolyte Disorders
- Kidney Month
- Community Corners
- Physicians Corner
- Advanced Practice Providers Corner
- Nurses Corner
- Pharmacists Corner
- Dietitians Corner
- Payers Corner
- Tools
Archives
Supporting Organization Spotlight: IgA Nephropathy Foundation
As Rare Disease Day is February 28th, the NephU community would like to raise awareness about IgA Nephropathy, a rare kidney disease. NephU will spotlight one of their newest Supporting Organizations: The IgA Nephropathy (IgAN) Foundation. The NephU community will invite three guests from the IgAN Foundation’s leadership team to share with us who they are, what their mission is, and what resources they provide to the IgAN community.
*Bonnie Schneider, Carrie Enicke, and Gisela Delgado are unpaid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Jill Green is an employee of OPDC.
Featured Speakers
Bonnie Schneider
Director & Co-Founder-
IgA Nephropathy Foundation*
In 2004 Bonnie’s son was diagnosed with IgAN and after finding a lack of information available and hearing that there was no ongoing research to find a cure, she quit her job in marketing and started the IgA Nephropathy Foundation with her husband, Ed Bonnie works full time as Director of the Foundation.
Carrie Enicke
Vice President of Industry Relations & Programs-
IgA Nephropathy Foundation*
Carrie is a warrior Mom who lives with her husband and daughter in North Carolina. Carrie’s 16 year old daughter has IgAN nonresponsive to treatment. It is Carrie’s mission to help change her daughter’s future as well as the patients we serve.
Gisela Delgado
Brand Creative Director-
IgA Nephropathy Foundation*
Gisela was diagnosed with IgAN at the age of 14, and ultimately reached kidney failure at the age of 38. Luckily, she received a pre-emptive transplant from her brother. Gisela’s primary focus at the Foundation is developing the brand to be the trusted resource for all IgAN patients and caregivers.
Jill A Green, PhD
Nephrology Senior Medical Science Liaison-
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Jill A Green, PhD, is a Senior Medical Science Liaison in the nephrology division at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr Green received her PhD in biomedical sciences, with a specialization in biochemical and molecular basis of disease. She went on to hold a research scientist role at The James Comprehensive Cancer Center at The Ohio State University, specializing in oncology pre-clinical research before taking a position as a Regulatory Compliance Officer where she managed thoracic oncology clinical trials at The James Cancer Hospital.
Dr Green has been a proud member of the PKD Foundation – Columbus, OH chapter for over 12 years where she has been active in fundraising and advocacy efforts.
Location
Online
Related Events
-
Social Determinants Of Racial Disparities In Chronic Kidney Disease
March 4 from 12:00 pm to 1:00 pm
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU 's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.
May 2020 MRC2.CORP.X.04767